Summary from the GEO: "While breast cancer patients with tumors that express estrogen receptor α (ER) generally respond well to hormone therapies that block ER’s actions, a significant number relapse. Approximately 30% of these recurrences harbor activating mutations in ER’s ligand binding domain. ER mutations have been shown to confer ligand-independent function to ER; however, much is still unclear...

Summary from the GEO: "While breast cancer patients with tumors that express estrogen receptor α (ER) generally respond well to hormone therapies that block ER’s actions, a significant number relapse. Approximately 30% of these recurrences harbor activating mutations in ER’s ligand binding domain. ER mutations have been shown to confer ligand-independent function to ER; however, much is still unclear...

Summary from the GEO: "While breast cancer patients with tumors that express estrogen receptor α (ER) generally respond well to hormone therapies that block ER’s actions, a significant number relapse. Approximately 30% of these recurrences harbor activating mutations in ER’s ligand binding domain. ER mutations have been shown to confer ligand-independent function to ER; however, much is still unclear...

This superseries is composed of the subseries: GSE148276, GSE148277, and GSE148278. Breast cancer patients with tumors that express estrogen receptor α (ER) at times harbor activating mutations in ER’s ligand binding domain. To investigate mutant ER’s molecular effects, multiple isogenic ER mutant cell lines for the two most common ER ligand binding domain mutations, Y537S and D538G, were developed....

Identification of protein-protein interaction (PPI) of a novel variant of estrogen receptor alpha in breast cancer cells

Identification of a novel variant of estrogen receptor alpha in breast cancer cells.

From the dbGaP study description: "The genomic evolution of breast cancers exposed to systemic therapy and its effects on clinical outcome have not been broadly characterized. We integrated the genomic sequencing of 1918 breast cancers, including 1501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. Functional mutations in ERBB2 and loss-of-function mutations...